Product Pipeline

Microbiome Therapeutics Pipeline
Microbiome Pharmaceuticals Discovery
Clinical programs

Phase 2a studies completed with MH002 in both Ulcerative Colitis and Pouchitis.

Read More
Microbiome Pharmaceuticals Preclinical
Preclinical programs

Parkinson’s disease.
Metabolic diseases (partnered).

Microbiome Pharmaceuticals Discovery Programs
Discovery programs

Ongoing program in spondylarthritis and autoimmune conditions.

Effective live biotherapeutics

Designed for efficacy, developed for synergy, produced as one.

Contact us